Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$26.42 USD
+0.52 (2.01%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $26.41 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Brokerage Reports
Myriad Genetics, Inc. [MYGN]
Reports for Purchase
Showing records 181 - 200 ( 244 total )
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Terminating Coverage Due to Analyst Departure.
Provider: COLLIERS SECURITIES
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: CMS Releases Preliminary Payment Methodology Continued Uncertainty for BRACAnalysis Reimbursement Until at Least November, Maintain NEUTRAL
Provider: COLLIERS SECURITIES
Analyst: HUSAIN J
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: CMS Releases Preliminary Payment Methodology Continued Uncertainty for BRACAnalysis Reimbursement Until at Least November, Maintain NEUTRAL
Provider: COLLIERS SECURITIES
Analyst: HUSAIN J